These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30549261)

  • 1. p27
    Podmirseg SR; Vosper J; Hengst L
    J Pathol; 2019 May; 248(1):3-5. PubMed ID: 30549261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoplasmic p27
    Calvayrac O; Nowosad A; Cabantous S; Lin LP; Figarol S; Jeannot P; Serres MP; Callot C; Perchey RT; Creff J; Taranchon-Clermont E; Rouquette I; Favre G; Pradines A; Manenti S; Mazieres J; Lee H; Besson A
    J Pathol; 2019 Jan; 247(1):60-71. PubMed ID: 30206932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
    Ling YH; Li T; Yuan Z; Haigentz M; Weber TK; Perez-Soler R
    Mol Pharmacol; 2007 Aug; 72(2):248-58. PubMed ID: 17456787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer.
    Viotto D; Russo F; Anania I; Segatto I; Rampioni Vinciguerra GL; Dall'Acqua A; Bomben R; Perin T; Cusan M; Schiappacassi M; Gerratana L; D'Andrea S; Citron F; Vit F; Musco L; Mattevi MC; Mungo G; Nicoloso MS; Sonego M; Massarut S; Sorio R; Barzan L; Franchin G; Giorda G; Lucia E; Sulfaro S; Giacomarra V; Polesel J; Toffolutti F; Canzonieri V; Puglisi F; Gattei V; Vecchione A; Belletti B; Baldassarre G
    J Pathol; 2021 Feb; 253(2):234-245. PubMed ID: 33140857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation of P27 expression and localization to phosphorylated AKT in non-small cell lung cancer].
    Miao LJ; Wang J; Li SS; Wu YM; Wu YJ; Wang XC
    Ai Zheng; 2006 Oct; 25(10):1216-20. PubMed ID: 17059763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.
    Lin TC; Tsai LH; Chou MC; Chen CY; Lee H
    Tumour Biol; 2016 Mar; 37(3):4017-23. PubMed ID: 26482622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIRT2 inhibits non-small cell lung cancer cell growth through impairing Skp2-mediated p27 degradation.
    Li Z; Huang J; Yuan H; Chen Z; Luo Q; Lu S
    Oncotarget; 2016 Apr; 7(14):18927-39. PubMed ID: 26942878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments.
    Masuda A; Osada H; Yatabe Y; Kozaki K; Tatematsu Y; Takahashi T; Hida T; Takahashi T; Takahashi T
    Am J Pathol; 2001 Jan; 158(1):87-96. PubMed ID: 11141482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK16 overexpressed in non-small cell lung cancer and regulates cancer cell growth and apoptosis via a p27-dependent mechanism.
    Wang H; Liu H; Min S; Shen Y; Li W; Chen Y; Wang X
    Biomed Pharmacother; 2018 Jul; 103():399-405. PubMed ID: 29674275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer.
    Osoegawa A; Yoshino I; Tanaka S; Sugio K; Kameyama T; Yamaguchi M; Maehara Y
    J Clin Oncol; 2004 Oct; 22(20):4165-73. PubMed ID: 15483027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression levels of cyclin-dependent kinase inhibitor p27 correlate with good responses to platinum-based chemotherapy in non-small cell lung cancer.
    Oshita F; Kameda Y; Nishio K; Tanaka G; Yamada K; Nomura I; Nakayama H; Noda K
    Oncol Rep; 2000; 7(3):491-5. PubMed ID: 10767357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53.
    Hirabayashi H; Ohta M; Tanaka H; Sakaguchi M; Fujii Y; Miyoshi S; Matsuda H
    J Surg Oncol; 2002 Dec; 81(4):177-84; discussion 184. PubMed ID: 12451621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling.
    Hulit J; Lee RJ; Li Z; Wang C; Katiyar S; Yang J; Quong AA; Wu K; Albanese C; Russell R; Di Vizio D; Koff A; Thummala S; Zhang H; Harrell J; Sun H; Muller WJ; Inghirami G; Lisanti MP; Pestell RG
    Cancer Res; 2006 Sep; 66(17):8529-41. PubMed ID: 16951165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p27
    Bencivenga D; Caldarelli I; Stampone E; Mancini FP; Balestrieri ML; Della Ragione F; Borriello A
    Cancer Lett; 2017 Sep; 403():354-365. PubMed ID: 28687353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer.
    Pateras IS; Apostolopoulou K; Koutsami M; Evangelou K; Tsantoulis P; Liloglou T; Nikolaidis G; Sigala F; Kittas C; Field JK; Kotsinas A; Gorgoulis VG
    Int J Cancer; 2006 Dec; 119(11):2546-56. PubMed ID: 16988944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.
    Kruck S; Merseburger AS; Hennenlotter J; Scharpf M; Eyrich C; Amend B; Sievert KD; Stenzl A; Bedke J
    BJU Int; 2012 May; 109(10):1565-70. PubMed ID: 21981759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells.
    Hung WC; Chang HC; Pan MR; Lee TH; Chuang LY
    Mol Pharmacol; 2000 Dec; 58(6):1398-403. PubMed ID: 11093779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cyclin-dependent kinase inhibitor p27 as a prognostic factor in advanced non-small cell lung cancer: its immunohistochemical evaluation using biopsy specimens.
    Ishihara S; Minato K; Hoshino H; Saito R; Hara F; Nakajima T; Mori M
    Lung Cancer; 1999 Dec; 26(3):187-94. PubMed ID: 10598929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rho/ROCK pathway inhibition by the CDK inhibitor p27(kip1) participates in the onset of macrophage 3D-mesenchymal migration.
    Gui P; Labrousse A; Van Goethem E; Besson A; Maridonneau-Parini I; Le Cabec V
    J Cell Sci; 2014 Sep; 127(Pt 18):4009-23. PubMed ID: 25015295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival.
    Del Pizzo JJ; Borkowski A; Jacobs SC; Kyprianou N
    Am J Pathol; 1999 Oct; 155(4):1129-36. PubMed ID: 10514396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.